What is Lantheus?
Lantheus is a radiopharmaceuticals and imaging agents company serving providers, payers, patients, labs, hospitals, researchers, or life-sciences commercial teams.
- Category
- Radiopharmaceuticals and imaging agents
- Headquarters
- Bedford, MA
- Founded
- See company profile and filings
- Employees
- Mid-market / scaled operating company
- Total funding
- Public company
- Status
- Public company; Nasdaq: LNTH
What is Lantheus?
Lantheus is a radiopharmaceuticals and imaging agents company headquartered in Bedford, MA.
Lantheus operates in radiopharmaceuticals and imaging agents and has reached a scaled mid-market profile rather than an early startup footprint. Its official site and investor/company materials position the business around PYLARIFY, DEFINITY, TechneLite, with customers using the company for repeatable operating workflows rather than one-off projects.
For sellers, Lantheus is useful to profile because the buying center is large enough to include specialized finance, IT, operations, procurement, and line-of-business owners. The company status is Public company; Nasdaq: LNTH, so the best live signals are current company announcements, investor materials where available, hiring patterns, product launches, and partner ecosystem activity.
What does Lantheus offer?
Lantheus's profile centers on PYLARIFY, DEFINITY, TechneLite, Radiopharmaceutical pipeline.
- PYLARIFY· Radiopharmaceuticals and imaging agents
- DEFINITY· Radiopharmaceuticals and imaging agents
- TechneLite· Radiopharmaceuticals and imaging agents
- Radiopharmaceutical pipeline· Radiopharmaceuticals and imaging agents
- PET imaging· Radiopharmaceuticals and imaging agents
- Microbubble ultrasound· Radiopharmaceuticals and imaging agents
How does Lantheus make money?
Lantheus makes money through commercial activity tied to radiopharmaceuticals and imaging agents.
Lantheus monetizes through the commercial model common to radiopharmaceuticals and imaging agents: a mix of product sales, subscriptions, usage, services, channel programs, or transaction volume depending on the operating unit. Public list pricing is not always available, so enterprise buyers usually evaluate packaging, contract scope, geographic coverage, implementation services, and support commitments.
The practical growth levers are account expansion, new product attach, channel reach, retention, and operational efficiency. For outbound teams, that means relevant sales angles usually connect to productivity, integration, compliance, data quality, margin improvement, customer experience, or faster execution across distributed teams.
Who leads Lantheus?
Lantheus's named executives should be verified on the official leadership or investor-relations page before outreach.
- Lantheus executive leadershipExecutive leadership teamCurrent as of June 2026Use the official leadership, governance, or investor-relations page for current named executives before outreach.
- Lantheus finance leadershipFinance / CFO organizationCurrent as of June 2026Often owns investor communication, procurement governance, and budget discipline.
- Lantheus technology or operations leadershipTechnology, product, operations, or security leadershipCurrent as of June 2026Likely stakeholder group for software, infrastructure, data, workflow, and operational-improvement purchases.
How do you contact Lantheus's leadership?
Lantheus should be contacted through official investor, media, partner, support, or sales routes unless a named executive publishes a direct address.
contact via https://www.lantheus.com- Lantheus investor relationsInvestor relations / corporate contactcontact via https://www.lantheus.com
How is Lantheus funded?
Lantheus's current status is Public company; Nasdaq: LNTH.
Lantheus's current capital profile is best understood through its current status: Public company; Nasdaq: LNTH. If the company is public, the relevant financing signals are annual reports, quarterly results, debt disclosures, buybacks, acquisitions, and capital allocation commentary rather than venture rounds.
If the company is private or recently acquired, the important seller signal is ownership context: sponsors or strategic owners often push standardization, operating metrics, procurement discipline, and integration work. In either case, budget timing should be inferred from current company announcements, earnings materials, product launches, hiring, and strategic initiatives rather than stale funding databases.
How did Lantheus get here?
Lantheus's history should be read through founding, scale-up, public/private ownership, and current product or market focus.
- FoundingLantheus is foundedThe company begins building in radiopharmaceuticals and imaging agents.
- Scale-upCommercial footprint expandsLantheus broadens its product, customer, or geographic reach.
- Capital marketsPublic company; Nasdaq: LNTHOwnership and financing context shapes procurement, reporting, and operating priorities.
- 2025Mid-market operating profileThe company operates with specialized teams and repeatable buying centers.
- June 2026Current profile refreshedProfile generated from official domain, current status, and public source references.
Who are Lantheus's competitors?
Lantheus competes with larger platform incumbents and focused specialists in radiopharmaceuticals and imaging agents.
- MedtronicGlobal medical-technology incumbent with broad device and care-management scale.
- Boston ScientificLarge medical-device company competing across interventional specialties.
- AbbottHealthcare company with diagnostics, diabetes care, devices, and nutrition scale.
- Johnson & Johnson MedTechLarge medtech and pharmaceutical incumbent with global commercial reach.
- StrykerOrthopedics, neurotechnology, and surgical equipment competitor with hospital relationships.
Lantheus — frequently asked questions
